These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36729213)

  • 1. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
    Shiota M; Miyake H; Takahashi M; Oya M; Tsuchiya N; Masumori N; Matsuyama H; Obara W; Shinohara N; Fujimoto K; Nozawa M; Ohba K; Ohyama C; Hashine K; Akamatsu S; Kamba T; Mita K; Gotoh M; Tatarano S; Fujisawa M; Tomita Y; Mukai S; Ito K; Tanegashima T; Tokunaga S; Eto M;
    Cancer Immunol Immunother; 2023 Jun; 72(6):1903-1915. PubMed ID: 36729213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
    Blas L; Shiota M; Miyake H; Takahashi M; Oya M; Tsuchiya N; Masumori N; Matsuyama H; Obara W; Shinohara N; Fujimoto K; Nozawa M; Ohba K; Ohyama C; Hashine K; Akamatsu S; Kamba T; Mita K; Gotoh M; Tatarano S; Fujisawa M; Tomita Y; Mukai S; Ito K; Tanegashima T; Tokunaga S; Eto M;
    Int J Urol; 2023 Sep; 30(9):788-796. PubMed ID: 37528632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
    Tanegashima T; Shiota M; Fujiyama N; Narita S; Habuchi T; Fukuchi G; Takamatsu D; Oda Y; Miyake H; Takahashi M; Oya M; Tsuchiya N; Masumori N; Matsuyama H; Obara W; Shinohara N; Fujimoto K; Nozawa M; Ohba K; Ohyama C; Hashine K; Akamatsu S; Kamba T; Mita K; Gotoh M; Tatarano S; Fujisawa M; Tomita Y; Mukai S; Ito K; Tokunaga S; Eto M
    J Immunol; 2024 Jul; 213(1):23-28. PubMed ID: 38758119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with
    Kobayashi M; Numakura K; Hatakeyama S; Muto Y; Sekine Y; Sasagawa H; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Ohyama C; Habuchi T
    Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35885987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
    Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
    Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
    J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
    Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
    J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
    Markham A
    Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
    Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
    Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
    Bando Y; Hinata N; Omori T; Fujisawa M
    BMJ Open; 2019 Dec; 9(12):e030522. PubMed ID: 31826889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
    Hinata N; Yonese J; Masui S; Nakai Y; Shirotake S; Tatsugami K; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Ochi K; Kaneko H; Uemura H
    Int J Clin Oncol; 2020 Aug; 25(8):1533-1542. PubMed ID: 32519026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab.
    Shao N; Wan F; Zhu Y; Ye D
    Med Sci Monit; 2019 Aug; 25():6518-6522. PubMed ID: 31469816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
    McFarlane JJ; Kochenderfer MD; Olsen MR; Bauer TM; Molina A; Hauke RJ; Reeves JA; Babu S; Van Veldhuizen P; Somer B; Gunuganti V; Schnadig I; George S; Page RD; Arrowsmith E; Jain RK; Zhang J; McHenry MB; Johansen JL; Vogelzang NJ
    Clin Genitourin Cancer; 2020 Dec; 18(6):469-476.e4. PubMed ID: 32641261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma.
    Albiges L; Barthélémy P; Gross-Goupil M; Negrier S; Needle MN; Escudier B
    Ann Oncol; 2021 Jan; 32(1):97-102. PubMed ID: 33010459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.
    Gorin MA; Patel HD; Rowe SP; Hahn NM; Hammers HJ; Pons A; Trock BJ; Pierorazio PM; Nirschl TR; Salles DC; Stein JE; Lotan TL; Taube JM; Drake CG; Allaf ME
    Eur Urol Oncol; 2022 Feb; 5(1):113-117. PubMed ID: 34049847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
    Vogelzang NJ; Olsen MR; McFarlane JJ; Arrowsmith E; Bauer TM; Jain RK; Somer B; Lam ET; Kochenderfer MD; Molina A; Doshi G; Lingerfelt B; Hauke RJ; Gunuganti V; Schnadig I; Van Veldhuizen P; Fleming M; Galamaga R; Gupta M; Hool H; Hutson T; Zhang J; McHenry MB; Johansen JL; Tykodi SS
    Clin Genitourin Cancer; 2020 Dec; 18(6):461-468.e3. PubMed ID: 32718906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.